Latest / The Peptide Effect / Trick or Treatment? A Halloween Guide to AOD, Cagrilintide, and Weight-Loss Peptides 🎃

Transcript

Trick or Treatment? A Halloween Guide to AOD, Cagrilintide, and Weight-Loss Peptides 🎃 · The Peptide Effect

• 0:00
  Before we begin, this episode is for education
• 0:03
  and entertainment and is not medical advice.
• 0:06
  Some of the compounds discussed are investigational,
• 0:09
  are not approved for weight management, or have
• 0:12
  limited human safety data. Nothing in this episode
• 0:15
  is a recommendation to buy, inject, combine,
• 0:19
  or change a medication. Decisions about treatment
• 0:22
  belong with a qualified healthcare professional
• 0:24
  who knows your medical history. Welcome to the
• 0:27
  Peptide Effect and Happy Halloween! Tonight,
• 0:30
  we are opening the door to a different kind of
• 0:32
  haunted house. Behind one door, there is a peptide
• 0:36
  promising to burn stubborn fat. Behind another,
• 0:39
  there is a hormone signal that might turn down
• 0:41
  the constant chatter about food. Somewhere upstairs,
• 0:45
  three metabolic receptors are having a very complicated
• 0:48
  conversation. And down in the basement, somebody
• 0:51
  on the internet is insisting that combining all
• 0:53
  of them is the secret nobody wants you to know.
• 0:56
  That last room needs better lighting. Tonight
• 0:58
  we are talking about peptides with a Halloween
• 1:01
  twist including a OD9604, cagrelantide, and the
• 1:06
  bigger world of appetite and weight management
• 1:08
  medications. We will separate interesting science
• 1:11
  from spooky marketing, explain what these compounds
• 1:14
  actually do, and explore why the scariest thing
• 1:17
  in this space is sometimes the confidence of
• 1:19
  the person selling the vial. There will be no
• 1:21
  haunted dosing schedules. No mystery mixing recipes.
• 1:25
  and absolutely no promises that a peptide can
• 1:28
  erase a Halloween weekend. But there will be
• 1:31
  science, a few skeletons in the marketing closet,
• 1:33
  and a much better understanding of what happens
• 1:36
  when our appetite, metabolism, and expectations
• 1:39
  all show up wearing different costumes. First,
• 1:43
  let us set the scene. It is Halloween night.
• 1:46
  There is a bowl of candy on the counter. You
• 1:48
  have already walked past it several times. The
• 1:51
  first time, you barely noticed. The second time
• 1:54
  you thought about a peanut butter cup. The third
• 1:56
  time your brain started negotiating. They are
• 1:59
  little. It is a holiday. There is protein in
• 2:02
  peanut butter. Now sometimes you simply want
• 2:05
  the candy. That is allowed. Enjoying food is
• 2:09
  part of being human. But sometimes the experience
• 2:12
  feels less like a choice and more like a radio
• 2:14
  that will not turn off. You are thinking about
• 2:17
  what to eat next while you are still eating.
• 2:19
  You are physically comfortable, but your attention
• 2:22
  keeps drifting back to the kitchen. People often
• 2:24
  call that food noise. Food noise is a useful
• 2:27
  everyday phrase, although it is not a single
• 2:30
  standardized diagnosis. It can describe persistent
• 2:33
  thoughts, cravings, planning, or mental preoccupation
• 2:37
  around food. Different people mean different
• 2:39
  things when they use it. That distinction matters
• 2:41
  because hunger, cravings, habit, and emotion
• 2:45
  are related, but they are not identical. Physical
• 2:48
  hunger might build gradually. A craving might
• 2:51
  arrive suddenly and demand one very specific
• 2:54
  thing. Habit might tell you to grab a snack because
• 2:57
  you always eat while watching a movie. Stress
• 2:59
  might make food feel comforting even when your
• 3:02
  stomach is already full. One person can experience
• 3:05
  all four in the same evening. So, when somebody
• 3:09
  says a peptide eliminated their appetite, we
• 3:12
  should ask what actually changed. Did they become
• 3:15
  comfortably satisfied with smaller meals? Did
• 3:18
  cravings become less intrusive? Did nausea make
• 3:21
  eating unpleasant? Did they stop enjoying food
• 3:23
  altogether? Those experiences are very different,
• 3:27
  even if they all produce the same social media
• 3:29
  caption. I am never hungry anymore. That sentence
• 3:33
  can describe relief. It can also describe a problem.
• 3:36
  The goal of a useful treatment is not to turn
• 3:39
  a person into a decorative skeleton who survives
• 3:41
  on coffee and determination. The goal is better
• 3:45
  health, with enough nutrition and enough comfort
• 3:48
  to live a normal life. Now, let us meet our first
• 3:51
  Halloween guest, AOD9604. The name sounds like
• 3:56
  a locked laboratory door. In peptide conversations,
• 4:00
  it is frequently introduced as a fat loss fragment
• 4:02
  associated with human growth hormone. That description
• 4:05
  has a scientific starting point. Yodi was developed
• 4:09
  from a modified fragment of the growth hormone
• 4:11
  molecule, with researchers exploring whether
• 4:14
  certain effects on fat metabolism could be separated
• 4:17
  from the broader actions of growth hormone. That
• 4:19
  is an interesting idea. But an interesting idea
• 4:22
  is the opening scene, not the ending. This is
• 4:25
  where we need to distinguish between a proposed
• 4:27
  mechanism and a demonstrated benefit. A mechanism
• 4:31
  explains how something might work. A clinical
• 4:34
  outcome tells us whether it actually helped people
• 4:37
  in a meaningful and measurable way. Those are
• 4:40
  different questions. You can imagine a compound
• 4:42
  encouraging a fat cell to release stored energy.
• 4:45
  But the body still has to do something with that
• 4:48
  energy. Fat metabolism is a continuous process
• 4:51
  involving storage, release, circulation and use.
• 4:55
  Opening the storage room does not guarantee that
• 4:58
  the contents leave the building. That is why
• 5:00
  the phrase fat burning can be so misleading.
• 5:03
  It sounds like a tiny bonfire has been lit inside
• 5:06
  the body and everything unwanted is disappearing
• 5:10
  into smoke. Biology is less theatrical. A change
• 5:14
  in one metabolic process does not automatically
• 5:16
  produce sustained weight loss, better health,
• 5:19
  or a smaller waste. AOD also carries a particularly
• 5:23
  important skeleton in its closet, disappointing
• 5:26
  human obesity research. In its review for a December
• 5:29
  2024 advisory committee meeting, the Food and
• 5:32
  Drug Administration described a lack of convincing
• 5:35
  evidence for obesity treatment. The agency noted
• 5:38
  that most of the identified studies did not show
• 5:41
  a weight reduction benefit over placebo and that
• 5:44
  the original obesity development program ended
• 5:46
  after an unsuccessful study. That does not mean
• 5:49
  every question about the molecule has been answered
• 5:51
  forever. It does mean that calling it a proven
• 5:54
  fat loss treatment goes beyond the evidence.
• 5:57
  Sometimes when this comes up somebody says, well,
• 6:00
  that research used a different formulation or
• 6:03
  route. That can be a legitimate research question.
• 6:07
  Different delivery methods can change absorption
• 6:09
  and exposure. But a reason to conduct another
• 6:12
  study is not the same as the result of that study.
• 6:16
  If someone believes a different version works
• 6:17
  better, the next step is to demonstrate that
• 6:20
  with reliable human evidence, we do not get to
• 6:23
  fill the gap with enthusiasm. And we definitely
• 6:26
  do not get to assume that an injectable product
• 6:29
  sold online has inherited the safety profile
• 6:31
  of something studied in a different form. Think
• 6:34
  of it like a Halloween costume. Two people can
• 6:37
  both be dressed as vampires, but that does not
• 6:39
  make them the same person. A shared name does
• 6:42
  not establish identical manufacturing, purity,
• 6:46
  delivery, or biological effects. There is another
• 6:49
  claim that deserves a flashlight. Targeted fat
• 6:52
  loss. The idea that a peptide will specifically
• 6:55
  remove belly fat, love handles or one stubborn
• 6:58
  area is extremely appealing. It is also a claim
• 7:01
  that requires direct evidence. Putting a product
• 7:04
  near an area does not establish that it selectively
• 7:07
  changes the fat underneath that spot. Your body
• 7:10
  is not a haunted mansion where you can point
• 7:12
  at one room and say, exercise this one. Claims
• 7:16
  about spot reduction need actual measurements
• 7:19
  and controlled comparisons. Before and after
• 7:22
  photos cannot reliably separate the effect of
• 7:25
  a compound from lighting, posture, overall weight
• 7:28
  change, or everything else happening in someone's
• 7:31
  life. So, where does that leave AOD? With a research
• 7:35
  story that is more uncertain than its marketing
• 7:38
  often suggests. Interesting origin, plausible
• 7:41
  questions, disappointing obesity results, a substantial
• 7:45
  gap between what is claimed and what has been
• 7:48
  demonstrated. Now, let us move into a different
• 7:51
  room. Cagrelin Tide. You might hear it shortened
• 7:54
  to Cagri, but its full name is Cagrelin Tide.
• 7:57
  And unlike AOD, its main story is not a growth
• 8:00
  hormone fragment. Its story centers on amylin.
• 8:04
  Amylin is a hormone released by the pancreas
• 8:07
  alongside insulin. It participates in the body's
• 8:10
  response to eating, including signals involved
• 8:12
  in fullness and the movement of food out of the
• 8:15
  stomach. If Halloween hunger is a party with
• 8:18
  too many people talking at once, amylin signaling
• 8:21
  is one of the systems helping communicate that
• 8:23
  dinner has happened. Not a moral judgment. Not
• 8:26
  a lecture about willpower. A biological message.
• 8:30
  That is one reason appetite science is so fascinating.
• 8:34
  The experience we describe as self -control is
• 8:36
  influenced by a network of signals moving between
• 8:39
  the digestive system, pancreas, brain, and other
• 8:42
  tissues. We make choices. but we make those choices
• 8:46
  inside a biological environment. If that environment
• 8:50
  is constantly shouting about food, an ordinary
• 8:53
  decision can require an extraordinary amount
• 8:55
  of mental effort. A medication that changes those
• 8:58
  signals may change the difficulty of the decision.
• 9:02
  That does not make the person weak before treatment
• 9:04
  or virtuous afterward. It means the conditions
• 9:07
  changed. Now, cagrelantide is often discussed
• 9:11
  alongside semaglutide. semaglutide -AX at the
• 9:15
  GLP -1 receptor, cagrelin -tide -AX through the
• 9:18
  amylin receptor system. They are different pathways,
• 9:21
  which is why researchers have studied them together.
• 9:24
  The studied combination is commonly called Cagre
• 9:27
  -SEMA. Here is a crucial distinction. Evidence
• 9:30
  about a specific combination in a clinical trial
• 9:33
  is evidence about that studied treatment under
• 9:35
  those conditions. It is not automatic evidence
• 9:38
  for every homemade combination someone gives
• 9:40
  a similar nickname. A clinical trial involves
• 9:43
  defined products, eligibility criteria, monitoring,
• 9:47
  and a structured plan for evaluating benefits
• 9:49
  and harms. That structure is part of the evidence.
• 9:54
  In the Redefine One trial, published in the New
• 9:56
  England Journal of Medicine in 2025, researchers
• 10:00
  studied the cagrelantide and semaglutide combination
• 10:03
  in adults with obesity or overweight with a related
• 10:05
  complication who did not have diabetes. Over
• 10:09
  68 weeks, The estimated average weight reduction
• 10:11
  was about 20 .4 % with the combination, compared
• 10:15
  with about 3 % with placebo, using an analysis
• 10:18
  that accounted for participants regardless of
• 10:21
  whether they stayed on treatment. Digestive side
• 10:23
  effects were common. Those findings are meaningful.
• 10:27
  They also need context. An average is not a promise.
• 10:31
  A person listening at home cannot take that number
• 10:34
  and circle an identical result on a calendar.
• 10:37
  Some people respond more. Some respond less.
• 10:40
  Some cannot tolerate treatment. Some have medical
• 10:44
  circumstances that make a particular option unsuitable.
• 10:47
  And those results belong to the combination.
• 10:50
  They should not be presented as though Cagrel
• 10:52
  and Tide alone produced the same outcome. That
• 10:55
  distinction gets lost surprisingly often. A headline
• 10:58
  mentions a combination. A social media post shortens
• 11:02
  the name. A seller copies the percentage. Suddenly,
• 11:05
  One component is wearing the entire trial result
• 11:08
  like a stolen Halloween costume. The numbers
• 11:11
  may look familiar, but the identity has changed.
• 11:15
  You may also see different percentages reported
• 11:17
  for the same study. Sometimes that happens because
• 11:21
  researchers are answering different statistical
• 11:23
  questions. One analysis asks what happened under
• 11:26
  a treatment strategy, including interruptions
• 11:29
  or discontinuation. Another estimates what might
• 11:32
  happen if people remained on treatment as planned.
• 11:35
  Neither number should be selected simply because
• 11:38
  it makes the most dramatic advertisement. The
• 11:41
  useful question is, what does this number actually
• 11:44
  represent? That question is less exciting than
• 11:47
  a transformation photo. It is also much more
• 11:50
  valuable. Now, let us talk about the part of
• 11:53
  appetite suppression that deserves more attention.
• 11:56
  Eating less is not automatically eating well.
• 11:59
  A smaller appetite can make it easier to reduce
• 12:02
  excess intake. It can also make it easier to
• 12:04
  miss protein, fluids, vitamins, and minerals.
• 12:08
  Someone can feel delighted that food is finally
• 12:11
  quiet, then realize they have spent the entire
• 12:14
  day on a few bites and a beverage. The silence
• 12:17
  may feel good. The nutritional gap still matters.
• 12:21
  Imagine turning down the music at a Halloween
• 12:23
  party. Wonderful. Now you can hear yourself think.
• 12:27
  But if you also turn off the electricity, lock
• 12:29
  the kitchen, and forget to give anyone water,
• 12:32
  the party has developed a different problem.
• 12:35
  The aim is an appetite that allows adequate nourishment,
• 12:38
  not an appetite that disappears so completely
• 12:41
  that eating becomes an afterthought. This becomes
• 12:44
  especially relevant for people with a history
• 12:46
  of bariatric surgery, difficulty maintaining
• 12:48
  nutrition, or medical conditions that already
• 12:51
  complicate eating and hydration. Two people can
• 12:54
  have the same body weight and very different
• 12:56
  nutritional needs. Two people can lose the same
• 12:59
  number of pounds and have very different experiences
• 13:02
  of strength, energy and health. That is why the
• 13:05
  scale should never be the only narrator. A scale
• 13:08
  cannot tell you whether you are getting weaker
• 13:11
  when you stand up from a chair. It cannot tell
• 13:13
  you whether constipation is making you miserable.
• 13:17
  It cannot tell you whether you are avoiding meals
• 13:19
  because you feel nauseated. It gives one measurement,
• 13:23
  useful but incomplete. If the scale is moving
• 13:26
  while your ability to function is falling apart,
• 13:28
  that is information worth taking seriously. Let
• 13:31
  us open the next door. Semaglutide and Terzepotide.
• 13:35
  These names often travel through peptide conversations
• 13:38
  together, but they are not interchangeable. Semaglutide
• 13:42
  acts at the GLP -1 receptor. Terzepotide acts
• 13:46
  at both the GIP and GLP -1 receptors. Those receptor
• 13:50
  names describe biological targets. They are not
• 13:53
  a ranking system where a higher count automatically
• 13:55
  means a better choice for every person. More
• 13:58
  targets can create different effects. They can
• 14:01
  also create different questions. A person's response
• 14:04
  depends on far more than the number of receptors
• 14:07
  printed in a graphic. Medical history, tolerability,
• 14:11
  treatment goals, access, and the evidence for
• 14:13
  a particular use all matter. This is where the
• 14:17
  Halloween metaphor becomes useful again. A haunted
• 14:20
  house with three floors is not automatically
• 14:22
  a better house than one with two. You still need
• 14:25
  to know what is happening on each floor, whether
• 14:27
  the stairs are safe, and whether the lights work.
• 14:30
  Counting rooms is not an inspection. In the same
• 14:33
  way, saying a medication has two or three actions
• 14:36
  does not replace understanding the actual outcomes.
• 14:39
  There is also a language problem in this space.
• 14:42
  People often use the phrase GLP -1 as a casual
• 14:46
  label for almost every medication or investigational
• 14:49
  compound connected with weight loss. But cagrelantide
• 14:52
  is an amylin analog. AOD is a different kind
• 14:55
  of molecule entirely. Putting everything under
• 14:58
  one nickname makes conversation easier, but it
• 15:01
  can make understanding worse. If we want useful
• 15:04
  conversations, we need enough precision to know
• 15:06
  which compound, which pathway, and which evidence
• 15:10
  we are discussing. That brings us to Rietatrutide.
• 15:13
  Rietatrutide has drawn attention as an investigational
• 15:16
  medication designed to act at three receptor
• 15:18
  systems, GLP -1, GP, and glucagon. The glucagon
• 15:23
  part often catches people off guard. Many listeners
• 15:26
  know glucagon as a hormone involved in raising
• 15:29
  blood glucose. So, why would that pathway appear
• 15:33
  in a medication being studied for metabolic disease?
• 15:36
  Because hormones do more than one thing, and
• 15:38
  the effect of a carefully designed molecule depends
• 15:41
  on the balance of its actions. It is not a matter
• 15:44
  of adding three slogans together. One receptor
• 15:47
  for appetite, another for something else, a third
• 15:51
  for extra fat burning. That sounds tidy, but
• 15:54
  the actual biology is interconnected. The important
• 15:57
  questions remain practical. What happens to weight?
• 16:01
  What happens to blood glucose? What happens to
• 16:04
  tolerability? which outcomes improve, and which
• 16:07
  risks emerge. A mechanism helps researchers decide
• 16:11
  what to test. The trials determine whether the
• 16:14
  idea delivers. And a promising investigational
• 16:17
  medication is still different from a bottle purchased
• 16:19
  from an online research supplier. Even if the
• 16:22
  label carries the same name, the evidence does
• 16:25
  not establish what is inside that particular
• 16:27
  bottle. That is a manufacturing question, an
• 16:30
  identity question, and a quality question. Which
• 16:33
  brings us to one of the biggest jump scares in
• 16:35
  the entire peptide world. The research label.
• 16:39
  A bottle can look professional. It can arrive
• 16:41
  in a neat box. It can have a batch number, a
• 16:44
  printed label, and a document covered in scientific
• 16:47
  language. None of those details independently
• 16:50
  proves that it is appropriate for human injection.
• 16:53
  A purity percentage is not a complete safety
• 16:56
  assessment. Even an authentic test measuring
• 16:59
  chemical purity does not automatically establish
• 17:01
  sterility. the absence of bacterial toxins, accurate
• 17:05
  concentration, or stability after storage. Those
• 17:09
  are separate questions. Think about a Halloween
• 17:11
  candy apple. You might know the apple variety.
• 17:14
  You might know how much sugar is in the coating.
• 17:17
  That still does not tell you whether it was prepared
• 17:19
  hygienically or stored safely. Knowing one characteristic
• 17:23
  does not answer every other question. And when
• 17:26
  it comes to injected products, the consequences
• 17:29
  of those unanswered questions can be serious.
• 17:32
  The Food and Drug Administration has raised concerns
• 17:35
  about AOD products involving potential immune
• 17:37
  reactions and peptide impurities. It has also
• 17:41
  stated that cagrelantide and redetrutide cannot
• 17:44
  be used in compounding under federal law. A research
• 17:47
  label does not turn these products into approved
• 17:49
  medicines. Now, let us visit the internet's favorite
• 17:53
  haunted room, the stack. If one compound seems
• 17:56
  helpful, surely two will be better. If two are
• 17:59
  interesting, three must be advanced. That is
• 18:02
  the sales pitch. But combining compounds does
• 18:05
  not simply add their benefits while leaving their
• 18:08
  risks politely outside. Effects can overlap.
• 18:12
  Side effects can accumulate. One compound can
• 18:15
  make it harder to recognize what another is doing.
• 18:18
  If someone starts several products close together,
• 18:20
  then develops persistent nausea, which one caused
• 18:23
  it? If appetite drops so much that they cannot
• 18:26
  eat adequately, which change needs to be reconsidered?
• 18:29
  If they feel unwell, A complicated stack can
• 18:33
  turn a straightforward question into a detective
• 18:35
  story with too many suspects. And contrary to
• 18:39
  the advertisements, complexity is not proof of
• 18:42
  sophistication. Sometimes, the most useful information
• 18:46
  comes from being able to identify one intervention,
• 18:49
  one goal, and one observable response. There
• 18:52
  is a big difference between studying a combination
• 18:54
  deliberately and combining products because each
• 18:57
  one has an appealing description. AOD for fat.
• 19:01
  Cagrelentide for hunger. Something else for energy.
• 19:05
  Another thing to balance the side effects of
• 19:07
  the first three. At some point, the haunted house
• 19:10
  is being held together with extension cords.
• 19:13
  The missing piece is often not another molecule.
• 19:16
  It is a clear understanding of what problem is
• 19:18
  being treated, what evidence supports the approach,
• 19:21
  and how success and harm will be recognized.
• 19:24
  Now, let us talk about a monster that appears
• 19:27
  every Halloween. The idea that food requires
• 19:30
  punishment. You ate candy, so tomorrow you have
• 19:33
  to compensate. You enjoyed a party, so now you
• 19:36
  need a metabolic reset. You had dessert, so perhaps
• 19:40
  a stronger appetite suppressant will cancel it
• 19:42
  out. That story can make ordinary eating feel
• 19:45
  like a moral emergency. A piece of candy does
• 19:48
  not require an antidote. A holiday meal does
• 19:51
  not mean your treatment has failed. And enjoying
• 19:54
  food does not disqualify you from caring about
• 19:57
  your health. The useful distinction is between
• 19:59
  a pattern that supports your needs and a pattern
• 20:02
  that repeatedly creates problems. One evening
• 20:05
  rarely tells the whole story. After a salty meal,
• 20:09
  a higher scale reading may reflect fluid changes.
• 20:12
  After eating more carbohydrate, stored carbohydrate
• 20:15
  and its associated water can influence weight.
• 20:19
  Food moving through the digestive tract also
• 20:21
  has weight. The next morning's number is not
• 20:24
  a detailed report of new body fat. Treating every
• 20:27
  fluctuation like a crisis can lead to impulsive
• 20:30
  decisions that create more trouble than the original
• 20:33
  meal. The body is not a courtroom and the bathroom
• 20:36
  scale is not a judge. You can return to your
• 20:39
  usual eating pattern without turning the next
• 20:41
  day into a punishment ritual. There is another
• 20:44
  reason to avoid chasing a dramatic overnight
• 20:46
  correction. Sometimes, what people celebrate
• 20:49
  as rapid progress is partly dehydration or reduced
• 20:53
  food intake from feeling sick. A lower number
• 20:55
  is not automatically a better outcome. If you
• 20:58
  are repeatedly vomiting, cannot keep fluids down,
• 21:02
  have severe or persistent abdominal pain, or
• 21:05
  feel faint or confused, that deserves medical
• 21:08
  attention. Those symptoms should not be treated
• 21:10
  as proof that a compound is working especially
• 21:13
  well. The haunted soundtrack does not make a
• 21:16
  warning signal less real. Now, imagine three
• 21:19
  listeners finishing the same Halloween party.
• 21:21
  One enjoyed dinner, had a few treats, and went
• 21:25
  home satisfied. Another kept eating despite feeling
• 21:28
  uncomfortably full because food thoughts were
• 21:30
  difficult to disengage from. A third barely ate
• 21:33
  at all because a treatment left them nauseated.
• 21:36
  Those people do not need the same response. The
• 21:39
  first may not have a problem to solve. The second
• 21:41
  may benefit from a thoughtful conversation about
• 21:44
  appetite, habits, sleep, stress, and appropriate
• 21:47
  treatment options. The third may need a review
• 21:50
  of tolerability and nutritional intake. Calling
• 21:53
  all three situations a failure of discipline
• 21:56
  would miss what is actually happening. This is
• 21:59
  why good questions are more useful than harsh
• 22:01
  judgments. What changed? When did it change?
• 22:05
  Is this physical hunger, a craving, nausea, or
• 22:09
  a familiar routine? Is the person eating enough
• 22:12
  to function? Are symptoms improving or getting
• 22:14
  worse? The more accurately we describe the experience,
• 22:18
  the more useful the next conversation becomes.
• 22:21
  Let us bring our main characters back together.
• 22:24
  Yodi is often presented through a fat metabolism
• 22:26
  story, but its obesity evidence does not support
• 22:29
  the certainty of many advertisements. Cagrelentide
• 22:33
  is an amylin analog with a clinical research
• 22:35
  story centered on appetite and weight management,
• 22:39
  including studies with semaglutide. Semiglutide
• 22:42
  and Terzepotide have distinct receptor actions
• 22:44
  and established medical uses, depending on the
• 22:47
  specific product. Rita Trutide explores a different
• 22:50
  combination of receptor activity in clinical
• 22:53
  research. Those are separate stories. They do
• 22:56
  not become equivalent because they all appear
• 22:58
  in the same online shop or the same conversation
• 23:01
  about weight loss. And none of them should be
• 23:04
  understood through the fantasy that a body can
• 23:06
  be forced into health by eliminating hunger as
• 23:08
  aggressively as possible. Hunger is information.
• 23:12
  Fullness is information. Side effects are information.
• 23:16
  The aim is to interpret those signals, not declare
• 23:19
  war on every sensation. Before we finish, here
• 23:23
  is a little Halloween test for the next peptide
• 23:25
  claim you encounter. Imagine taking away the
• 23:28
  dramatic music, the transformation picture, the
• 23:31
  discount code, and the glowing vial. What remains?
• 23:35
  Is there a controlled human study? Was the actual
• 23:38
  compound tested? Was it tested by the same route?
• 23:41
  Were the people in the study similar to the people
• 23:43
  being targeted by the claim? Was the outcome
• 23:46
  something meaningful or just a laboratory method?
• 23:49
  They are how knowledge becomes more reliable.
• 23:52
  The most exciting future in peptide medicine
• 23:55
  is not a future where every new molecule gets
• 23:58
  called a miracle. It is a future where useful
• 24:00
  treatments are identified carefully, disappointing
• 24:03
  ideas are recognized honestly, and people can
• 24:07
  make decisions with better information. That
• 24:09
  is worth being curious about. So, this Halloween,
• 24:12
  enjoy the atmosphere. Admire the orange lights.
• 24:16
  Put on the black lipstick. Watch the ridiculous
• 24:19
  horror movie where someone insists on investigating
• 24:22
  a noise in the basement alone. And when the next
• 24:25
  miracle peptide appears in your feed, bring a
• 24:27
  flashlight. Ask what it does. Ask what has actually
• 24:31
  been demonstrated. Ask whether the result belongs
• 24:34
  to that compound or a different treatment wearing
• 24:36
  the same costume. Most of all, remember that
• 24:39
  your health is bigger than your appetite, your
• 24:42
  weight, or one night with a candy bowl. A useful
• 24:45
  treatment should support the life you want to
• 24:47
  live. Enough energy to participate. Enough nourishment
• 24:51
  to stay strong. Enough comfort to enjoy your
• 24:54
  day. And enough understanding to recognize when
• 24:57
  a claim deserves your attention and when it deserves
• 25:00
  to be left outside with the plastic skeletons.
• 25:03
  One final reminder. This episode is educational
• 25:06
  and is not medical advice. Research findings
• 25:09
  do not establish that an online peptide product
• 25:12
  is safe, effective or suitable for you. Work
• 25:15
  with a qualified healthcare professional before
• 25:18
  starting, stopping or combining treatments and
• 25:21
  seek care for severe or persistent symptoms.
• 25:24
  Happy Halloween from the peptide effect. May
• 25:27
  your costumes be dramatic, your questions be
• 25:30
  thoughtful and your science hold up when the
• 25:32
  lights come on. And as always, thanks for listening,
• 25:36
  keep learning and stay curious.